CVKD
CadrenalยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CVKD Profile
Cadrenal Therapeutics, Inc.
A biopharmaceutical company for the prevention of cardiogenic systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation
822 A1A North, Suite 306, Ponte Vedra, Florida 32082
--
Cadrenal Therapeutics, Inc., was registered as a Delaware corporation on January 25, 2022. The company is developing the company's drug candidate ticafalin for unmet need in anticoagulation therapy. Ticafalin is an advanced novel oral and reversible anticoagulant (blood thinner) for the prevention of heart attack, stroke, and death from blood clots in patients with rare cardiovascular diseases that require chronic anticoagulation.
